APAC Non-Hodgkin Lymphoma Market to Grow at 6.6% CAGR Through 2020,...

New research report “Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting” elaborated by GBI Research is now...(PRWeb September 26, 2014)Read the full story at http://www.prweb.com/releases/2014/09/prweb12203364.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Cannavale K, Xu H, Xu L, Sattayapiwat O, Rodriguez R, Bohac C, Page J, Chao C Abstract INTRODUCTION: Anemia is a common adverse effect of myelosuppressive chemotherapy, and the development of chemotherapy-induced anemia (CIA) is more common in patients with hematologic malignant tumors. OBJECTIVE: To assess the incidence and treatment pattern of CIA in patients diagnosed with non-Hodgkin lymphoma (NHL) from a large managed care organization in California. METHODS: Patients diagnosed with NHL between 2010 and 2012 were studied to provide an updated picture of CIA in current hematology-oncology pract...
Source: The Permanente journal - Category: General Medicine Tags: Perm J Source Type: research
Publication date: Available online 17 July 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Fernando Cabanillas, Noridza Rivera, Mirelis Acosta, Wandaly Pardo, Pedro Solivan, Caroline Rivera, Idalia LiboyAbstractBackgroundOur objective was to evaluate the impact of lenalidomide in patients with aggressive lymphoma who attained
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Panniculitis-like T-cell lymphoma is an uncommon type of non-Hodgkin lymphoma, occurring usually in the form of nodules within the subcutaneous fat tissue of the extremities or trunk. In the literature, subcut...
Source: Diagnostic Pathology - Category: Pathology Authors: Tags: Case Report Source Type: research
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
No optimal salvage therapy for relapsed/refractory aggressive histological types of non-Hodgkin lymphoma exists. We explored a combination of single-agent lenalidomide following gemcitabine, rituximab, oxaliplatin combination ( “GROC-Rev”) in 33 patients. We observed a response rate of 61% (39% complete response rate) and 3-year overall survival of 47%, superior to previous experience. GROC-Rev is a new salvage regimen with encouraging results.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
A novel antibody-drug conjugate (ADC) for adults with refractory or relapsing diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma, has received accelerated FDA approval. Up to 40% of patients with DLBCL will relapse.
Source: JAMA - Category: General Medicine Source Type: research
AbstractPurpose of ReviewIMiDs are a class of biologic agents with immunomodulatory, anti-angiogenic, and direct anti-cancer activities. This review summarizes current data on clinical development and application of IMiDs in non-Hodgkin lymphoma (NHL) subtypes, focusing primarily on lenalidomide, with additional discussion on managing common side effects.Recent FindingsImproved upon the prototype thalidomide, the second-generation compound lenalidomide has enhanced immunological and anti-cancer properties with fewer side effects, while next-generation small molecule cereblon/E3 ubiquitin ligase modulator CC-122 is in early...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
ConclusionsBaseline TMTV and TLG are both strong independent prognostic factors for pediatric B-NHL and provide a potential approach to aid in risk sub-stratification, especially in patients with high-risk disease.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Conclusion: When clinicians encounter a lesion associated with mandibular canal widening, they should immediately consider these entities in the differential diagnosis. Doing so will help dentists make more accurate diagnoses and develop better treatment plans based on patients' radiographs. PMID: 31281785 [PubMed]
Source: Imaging Science in Dentistry - Category: Dentistry Tags: Imaging Sci Dent Source Type: research
CONCLUSIONS: NRP-1 exhibited higher expression in lymphomas, and it was positively expressed in EBV-positive lymphomas. Moreover, highly expressed NRP-1 can be used as an undesirable independent prognostic factor in NHL. PMID: 31282408 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
More News: Lymphoma | Non-Hodgkin's Lymphoma | Pharmaceuticals